Evidence-Based Oncology > February 2018

Evidence-Based Oncology - February 2018

February 17, 2018 – Dave Nellesen, PhD; Katerine Dea, MSc; Annie Guerin, MSc; Kenneth W. Culver, MD; Alex Mutebi, PhD; and Anand Dalal, MBA, BSPharm
February 19, 2018 – Dave Nellesen, PhD; Katerine Dea, MSc; Annie Guerin, MSc; Kenneth W. Culver, MD; Alex Mutebi, PhD; and Anand Dalal, MBA, BSPharm
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
February 20, 2018 – Mary Caffrey
Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care. 
February 20, 2018 – Samantha DiGrande
Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery. 
February 21, 2018 – Mary Caffrey
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
February 24, 2018 – Joseph Alvarnas, MD
Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.